ArticleThe American journal of managed care2018
Monitoring the hepatitis C care cascade using administrative claims data.
Article in The American journal of managed care, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Comorbidities Associated With Chronic Hepatitis C Among Medicaid Beneficiaries, 2016-2020.American journal of preventive medicine · 2026Article
- Trends in Utilization and Costs Following a Hepatitis C Elimination Initiative.JAMA network open · 2026Observational
- Hepatitis C Treatment in Kentucky Medicaid Recipients with Concurrent Opioid Use Disorder: A Cross-Sectional Study.Journal of general internal medicine · 2025Article
- Disparities in Linkage to Care Among Children With Hepatitis C Virus in the United States.Pediatrics · 2025Article
- Racial and Ethnic Disparities in Hepatitis C Care in Reproductive-Aged Women With Opioid Use Disorder.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Association between claims-based setting of diagnosis and treatment initiation among Medicare patients with hepatitis C.Health services research · 2024Article
- Hepatitis C Cascades: Data to Inform Hepatitis C Elimination in the United States.Public health reports (Washington, D.C. : 1974) · 2023Review
- Hepatitis C Treatment Initiation Among US Medicaid Enrollees.JAMA network open · 2023Article
- Hepatitis C Virus Testing and Care Cascade Among Transgender and Gender Diverse Individuals.American journal of preventive medicine · 2023Article
- The Hepatitis C Care Cascade During the Direct-Acting Antiviral Era in a United States Commercially Insured Population.Open forum infectious diseases · 2022Article
- Disparities in the quality of care for chronic hepatitis C among Medicare beneficiaries.PloS one · 2022Article
- Hepatitis C Care Cascades for 3 Populations at High Risk: Low-income Trans Women, Young People Who Inject Drugs, and Men Who Have Sex With Men and Inject Drugs.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Linkage to specialty care in the hepatitis C care cascade.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2021Article
- The Use of Administrative Data to Investigate the Population Burden of Hepatic Encephalopathy.Journal of clinical medicine · 2020Review
- Accelerating the elimination of hepatitis C in Kuwait: An expert opinion.World journal of gastroenterology · 2020Review
- Statewide Assessment of the Hepatitis C Virus Care Cascade for Incarcerated Persons in Vermont.Public health reports (Washington, D.C. : 1974)Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectivesWith the availability of curative therapies, it is important to ensure that individuals infected with hepatitis C virus (HCV) receive recommended testing, care, and treatment. We sought to evaluate insurance claims data as a source for monitoring progression along the HCV care cascade. STUDY
designLongitudinal evaluation of disease progression, from diagnosis to treatment, among commercially insured enrollees with chronic HCV.
methodsWe validated and used algorithms derived from standardized procedure and diagnosis codes to identify enrollees with chronic HCV in large insurance claims databases to describe the HCV care cascade, including the proportion engaged in HCV-specific care (13 possible definitions), the proportion prescribed HCV treatment, and the proportion who received an HCV RNA test 30 or more days after initiating treatment.
resultsApproximately 90% of individuals with an HCV RNA test procedure code followed by either 3 or more chronic HCV diagnosis codes on different service dates or 2 or more chronic HCV diagnosis codes separated by more than 60 days truly had chronic HCV. Using these algorithms, we identified 5791 HCV cases from January 1, 2013, to June 30, 2014. Among enrollees with HCV, 95% were engaged in HCV care, but only 49% initiated treatment and 43% received a follow-up HCV RNA test 30 or more days after initiating treatment.
conclusionsWith validated case-finding algorithms, insurance claims data can be used to describe and monitor portions of the HCV care cascade. Although nearly all enrollees with HCV were engaged in HCV care, only half received treatment, indicating that even commercially insured enrollees may find it challenging to access treatment.
Indexed as
Identifiers
29851440PMC6371394What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.